Back to EXEL
EXEL: Cabometyx Strength, Valuation Questions
$EXELNEUTRALBiotechnology

EXEL: Cabometyx Strength, Valuation Questions

Exelixis reported another quarter of beats driven by Cabometyx, strong cash flow and an advancing zanzalintinib program. The stock trades near its 52-week high, while analyst targets sit below the market price, creating a mixed risk-reward backdrop.

October 31, 202610 min read
Current Price
$69.39
+4.82%
Analyst Rating
Hold
Price Target
$53.00
-23.6% upside
P/E Ratio
20.11

Executive Summary

Investment Thesis: Exelixis, $EXEL, has shown recurring operational strength driven by its cabozantinib franchise, producing consecutive quarterly EPS beats and robust cash flow. The company carries a strong balance sheet, high ROE and active share repurchases, while pipeline progress on zanzalintinib represents a medium-term growth catalyst. At the same time, the stock trades near its 52-week high and consensus price targets imply notable downside, so valuation and near-term catalyst timing merit close attention.

Current Price: $69.39 (as of Friday, October 30) | Key Metric: P/E Ratio: 20.11 | Stance: NEUTRAL

Company Overview

Exelixis, Inc. operates in oncology drug discovery and development, commercializing small-molecule therapies and advancing a clinical-stage pipeline. The company is best known for cabozantinib, marketed as Cabometyx and Cometriq in various indications, and it's advancing zanzalintinib and other programs.

Key Products & Competitive Position

  • Core Business: Oncology-focused biopharma with a commercial franchise and pipeline assets.
  • Key Products: Cabometyx (cabozantinib) franchise, pipeline candidate zanzalintinib, and earlier-stage programs.
  • Competitive Moat: Clinical data and label breadth for cabozantinib create durable revenue streams, while partnering and in-house development strengthen market reach. Strong gross margins and cash generation support continued R&D and capital allocation choices.

Recent Developments

Q3 2026 results released on October 29 showed revenue of approximately $659 million and adjusted EPS of $0.94, ahead of consensus. Management highlighted continuing Cabometyx sales strength, acceleration of share repurchases, and pipeline progress including zanzalintinib. The company emphasized margin leverage and free cash flow generation, and commentary on commercial traction has been positive across calls and transcripts.

Financial Snapshot

Market Cap$17.44B
P/E Ratio20.11
52-Week Range$36.00 - $72.10
Dividend Yield0.0%
EPS (TTM)$3.59
ROE45.54%

Revenue & Earnings Trends

Revenue has grown from roughly $1.61B in 2022 to roughly $2.32B in 2025 and further into 2026, with 2026 YTD results supported by Cabometyx. The company reported consecutive quarterly EPS beats, with Q3 2026 adjusted EPS of $0.94 versus an estimate of $0.887. Analysts note year-over-year revenue growth in the low double digits and improving profitability, reflected in margin expansion and rising free cash flow.

Balance Sheet Highlights

Exelixis carries low net debt, with roughly $892M cash against $162M debt according to extracted data. The current ratio sits at 3.21 and the quick ratio near 2.96, indicating strong short-term liquidity. Operating cash flow and free cash flow have been robust, supporting buybacks and R&D spend without the need for large external financing.

Valuation Analysis

Current Valuation Metrics

Forward P/E~15.7 (estimate)vs Industry: ~18-25
PEG Ratio0.87Growth-adjusted
EV/EBITDA~16.2vs Historical: higher after rally
P/S Ratio~7.0vs Peers: above some peers

Historical Comparison

Current multiples sit toward the higher end of Exelixis's recent trading range after a strong year-to-date rally. Trailing P/E of 20.11 reflects both improved earnings and a rising share price; PEG below 1.0 suggests the market is pricing earnings growth into the multiple. Investors should note short-term multiple expansion has contributed meaningfully to recent returns.

Fair Value Estimate

Combining a multiples approach and conservative DCF assumptions, a fair value range could be framed around $50 to $65 per share, with a midpoint near $57. That range reflects solid cash flow, low leverage, and continued Cabometyx revenue, balanced against execution and regulatory timing risk. Analysts' mean target of $53 implies downside from the current price, while a bullish scenario that assumes faster-than-expected zanzalintinib uptake would justify values above the midpoint.

Competitive Landscape

Market Position

Market Share: meaningful within niche oncology indications | Ranking: mid-cap oncology player with notable commercial franchise

Key Competitors

$BMYLarge oncology portfolio and competing agents across multiple indications
$RHHBYGlobal oncology presence; scale in trials and commercialization
$BMY(Repeat competitor noted as other targeted therapies overlap in indications)

Competitive Advantages

  • Moat 1: Clinically validated cabozantinib franchise with multiple approved indications and established prescriber base.
  • Moat 2: Strong cash generation and low net debt, enabling continued investment in trials and disciplined capital return.
  • Moat 3: Focused oncology strategy and partnerships that extend commercial reach and development capacity.

Earnings Track Record

Last 4 Quarters: 4 beats / 0 misses

Recent Earnings History

Q4 2025$0.94 vs $0.81 estBEAT
Q1 2026$0.87 vs $0.76 estBEAT
Q2 2026$0.91 vs $0.86 estBEAT
Q3 2026$0.94 vs $0.92 estBEAT

Guidance Trend

Management has emphasized durable Cabometyx sales and margin leverage, and it has been active with share repurchases. Guidance commentary on the Q3 call suggested confidence in the near-term commercial momentum while noting that pipeline timing, including potential launches, will drive medium-term upside. Analysts will likely focus on FY2026 and FY2027 revenue cadence and any updated guidance at the next quarter.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 1 Buy: 6 Hold: 10 Sell: 0 Strong Sell: 1

Price Targets

  • Low: $49
  • Mean: $53 (-23.6% downside)
  • High: $60

Recent Analyst Actions

Following the Q3 release, broker commentary highlighted better-than-expected Cabometyx sales and reiterated a cautious view on near-term upside because many analysts still model conservative uptake for new pipeline launches. A plurality of analysts rate the stock as Hold, reflecting the divergence between operational strength and near-term valuation expectations.

Recent News & Catalysts

Key Developments

  • Q3 Earnings Beat: Exelixis topped Q3 2026 EPS and revenue estimates on Cabometyx strength and accelerating buybacks, per Zacks on 10/30/2026.
  • Earnings Call Commentary: Management reiterated commercial momentum and provided pipeline updates, as transcribed by Seeking Alpha on 10/29/2026.
  • Revenue Detail: MarketBeat and Zacks reported Q3 revenue around $659M, driven by the cabozantinib franchise and R&D progress toward a potential zanzalintinib launch.

Upcoming Catalysts

Next Earnings: Expected around Feb 2027 (quarterly calendar subject to company confirmation) | Key Events: regulatory updates for zanzalintinib, additional label or indication news for cabozantinib, quarterly revenue cadence, and updated capital allocation or buyback disclosures.

Technical Outlook

Current Price: $69.39 vs 52-Week High: $72.10 (-3.8% from high)

Trend Analysis

Price action through October shows a strong multi-month uptrend, with a sharp run in the last six months where the stock more than doubled from the 52-week low. Momentum indicators and relative strength versus the S&P 500 turned positive during the rally. Volume increased on earnings and news days, signaling institutional engagement. Still, the stock is trading close to its high, which often increases sensitivity to near-term news.

Key Levels

  • Resistance: $72, $80
  • Support: $60, $50

Bull vs Bear Case

Bull Case

  • Catalyst 1: Continued Cabometyx revenue growth and margin expansion, driving stronger-than-expected free cash flow.
  • Catalyst 2: Successful regulatory progress or commercial launch of zanzalintinib that materially expands the addressable market.
  • Catalyst 3: Continued share repurchases and efficient capital allocation that lift per-share metrics and investor sentiment.

Bull Target: $85 (+22.6%)

Bear Case

  • Risk 1: Regulatory setbacks or slower-than-expected uptake for pipeline assets, which would reduce growth visibility.
  • Risk 2: Competitive dynamics in oncology could pressure pricing or market share for cabozantinib-based regimens.
  • Risk 3: Valuation contraction if growth expectations disappoint, given the stock trades near its highs and analysts' mean targets are below the market price.

Bear Target: $45 (-35.1%)

Risks to Consider

  • Valuation Risk: The stock trades near the 52-week high and at elevated multiples relative to some peers, so any slowdown in growth could compress multiples.
  • Competitive Risk: Alternative therapies and new entrants in oncology can reduce pricing power or share for cabozantinib indications.
  • Macro Risk: Broader market volatility or risk-off periods tend to weigh on biotech and mid-cap equities, which could magnify drawdowns.
  • Execution Risk: Clinical trial results, regulatory timing or commercial execution for zanzalintinib and other pipeline programs can materially affect future cash flows.

Bottom Line

Investment Verdict: NEUTRAL

Exelixis presents a balanced profile: reliable cash generation and consistent earnings beats driven by Cabometyx support a positive operational outlook, while valuation near recent highs and analyst targets implying downside create caution. If you're watching the name, the key questions are whether pipeline catalysts arrive on schedule and whether Cabometyx can sustain current growth rates.

Action Items for Investors

  • Long-term investors: Monitor regulatory milestones for zanzalintinib and subsequent commercialization plans, and reassess position sizing as formal guidance or approvals are reported.
  • Short-term traders: Watch earnings cadence and near-term volume spikes, consider defined risk limits around support levels, and be mindful that trading near a 52-week high can increase volatility.
  • Risk management: Maintain diversification, set stop-loss or trimming rules that reflect your risk tolerance, and track upcoming catalyst dates and guidance revisions closely.

What to Watch This Week

  • Any follow-up analyst notes or model revisions after Q3 2026 commentary.
  • News on regulatory timing or trial readouts for zanzalintinib.
  • Share repurchase pacing and any updated capital allocation announcements.

Share this report

Share this article

Spread the word on social media

Think EXEL will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.